Novo Nordisk A/S (NVO) is fighting back against rising competition in the weight loss drug market with some serious price cuts and a new strategy to keep patients in its camp.
The company announced Monday that new self-pay patients can now get Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic for just $199 per month between now and March 31, 2026. It's an introductory offer that applies to the first two months of therapy on the two lowest doses.
After that honeymoon period ends, patients move to a new standard monthly self-pay price that Novo Nordisk is slashing from $499 down to $349. That's a 30% reduction from the previous rate, and it kicks in immediately.
The timing isn't coincidental. These pricing moves follow Novo Nordisk's recent agreement with the U.S. government to expand access to obesity and diabetes medications while simultaneously lowering prices in the direct-to-patient channel throughout 2026. Translation: the company is feeling heat from multiple directions and responding accordingly.
How to Access the New Pricing
Novo Nordisk has rolled out several pathways for patients to take advantage of the lower prices. You can go directly through wegovy.com or ozempic.com, register for the savings, and use them with a prescription at over 70,000 pharmacy locations nationwide.
There's also NovoCare Pharmacy, where healthcare providers send prescriptions directly and patients receive home delivery or can pick up at one of more than 9,000 CVS retail locations.
Additionally, the company is working with Costco Wholesale Corp (COST), GoodRx Holdings, Inc. (GDRX), WeightWatchers, Ro, LifeMD Inc. (LFMD), and eMed, among other participating organizations and select telehealth providers.
If you have commercial insurance coverage and qualify, Novo Nordisk's existing savings programs still let you pay as little as zero dollars per month for Wegovy or $25 per month for Ozempic.
The Pill Strategy
Beyond making the injections more affordable, Novo Nordisk is preparing for a major push with the Wegovy pill. CEO Mike Doustdar told Reuters on Monday that the company is entering the launch with ample supply and a more aggressive rollout strategy, specifically designed to avoid the shortages that plagued the injectable version and cost the company market share.
The company expects U.S. regulators to decide on approval by year-end. A pill option could significantly broaden demand by attracting patients who would rather swallow a tablet than deal with injections.
This matters because Novo's obesity franchise has hit some headwinds recently. Slowing growth, largely due to supply bottlenecks, opened the door for competitors like Eli Lilly (LLY) to chip away at Novo's early dominance in the weight loss drug market. The company clearly doesn't want to make the same mistake twice.
NVO Price Action: Novo Nordisk A/S stock was up 1.31% at $48.89 at publication on Monday.
